Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

Abstract The use of symptomatic medications represents a challenge for clinical trials of novel medicines designed to slow Parkinson’s disease progression. A time-to-event (TTE) approach using a defined motor progression milestone may mitigate the confounding effect of symptomatic therapy on the Mov...

Full description

Saved in:
Bibliographic Details
Main Authors: Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-025-01041-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41531-025-01041-9

Similar Items